Founders
Dr. Nilam Mangalmurti leads the scientific vision and research direction at Senticell. As a physician-scientist and Associate Professor of Medicine at the University of Pennsylvania, she brings deep expertise in red blood cell immunobiology and translational diagnostics. She oversees the design and execution of Senticell’s research programs, ensuring scientific rigor and alignment with the company’s mission.
Neha Shah, MBA, is a seasoned entrepreneur with a track record of leading high-impact ventures across healthcare and technology. She brings strategic leadership, operational insight, and a commitment to translating scientific discovery into scalable, real-world solutions.
Together, they are advancing a new frontier in cell-based diagnostics- bridging deep science with purposeful innovation to unlock the next generation of minimally invasive, precision healthcare.
Founder & Chief Scientific Advisor
Nilam Mangalmurti, MD
-
Defined critical immune functions of red blood cells, establishing RBC
immunobiology as a new field of study
-
Elected to ASCI, ATSF, research has been supported by NIH, DoD, ALA, NBF
-
Expertise in sepsis and critical illness
Co-founder & Chief Executive Officer
Neha Shah, MBA
-
25-year exited entrepreneur; co-founded and scaled GEP to over $1.1B in annual revenue, culminating in a multi-billion-dollar exit, supporting clients like J&J, BMS, and Roche
-
Board Chair, McNulty Leadership Program at The Wharton School; Henry Crown Fellow, Aspen Institute
Advisors
Senticell's advisors are globally recognized experts in immunology, oncology, and biotechnology. With decades of academic and industry leadership, they provide strategic insight to guide our scientific direction and platform development. Their experience spans tumor immunology, cytokine biology, and translational medicine-ensuring our approach remains bold, rigorous, and clinically impactful.
Scientific Advisor
Steven Albelda,
MD
-
Professor of Medicine at the Perelman School of Medicine, University of Pennsylvania
-
Scientific Advisor to Verismo Therapeutics and Bio4
-
Co-founder, Capstan
-
Tumor immunologist, lung cancer, immunotherapy, CAR T cells (co-founder of Capstan)
-
Wagner Award from the International Mesothelioma Interest Group
Scientific Advisor
Chris Hunter,
PhD
-
Cytokine biologist, inflammation expert, immunologist
-
Founder at Surface Oncology (acquired by Coherus)
-
Scientific Advisor for Anaptsys Bio, CytomX, Coherus, ArsenalBio and Synthekine
Scientific Advisor
David Roth, MD, PhD
-
Scientific interests in cancer biology, DNA repair, precision medicine, and DNA- based diagnostics
-
Former Chair of Pathology and Laboratory Medicine at The University of Pennsylvania Health System
-
Fellow, College of American Pathologists
-
Founder, Center for Personalised Diagnostics at Penn (clinical next generation sequencing in cancer)
-
Founder, Penn Center for Precision Medicine
Scientific Advisor
Mallik Srivatsan, PhD, MBA
-
Employee #1 at Momenta Pharmaceuticals (acquired by J&J for $6.5 billion)
-
Led strategy and fundraising at Mitra Biotech (now Farcast Life Sciences)
-
Founder & CEO of Accurius Therapeutics, a clinical-stage company developing lung-centric viral immunotherapies
-
Postdoctoral fellowship from MIT and an MBA from Wharton School
Life Sciences Innovator & Entrepreneur
Kartik Shah, MS, MBA
-
Founder & CEO - Tactile Therapeutics, developing molecular glues for neuro-inflammation
-
Founder & Director – Oxeia Biopharmaceuticals, leading first-in-class concussion drug
-
Former Head of Commercial Strategy- Atara Biotherapeutics, Commercial lead for $640m US rights deal
-
Advisor – StataDx, advancing point-of-care neurology diagnostics
-
Past – Cynvenio Biosystems, Oliver Wyman, GlobalXFunds (> $50B AUM)
-
Education - UPenn (Bioengineering & Biotechnology), Harvard MBA